- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Atossa Therapeutics Inc (ATOS)
Atossa Therapeutics Inc stock price live, this page displays NASDAQ ATOS stock exchange data. View the ATOS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Atossa Therapeutics Inc real time stock price chart below.
What Is the Atossa Therapeutics Inc Stock Price Today?
The Atossa Therapeutics Inc stock price today is 2.4400.
What Is the Stock Symbol for Atossa Therapeutics Inc?
The stock symbol for Atossa Therapeutics Inc is "ATOS."
What Stock Exchange Does Atossa Therapeutics Inc Trade On?
Atossa Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Atossa Therapeutics Inc a Good Stock to Buy?
Determining whether Atossa Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATOS quote. (ISIN: US04962H7044)
What Is the Atossa Therapeutics Inc Stock Price Today?
The Atossa Therapeutics Inc stock price today is 2.4400.
What Is the Stock Symbol for Atossa Therapeutics Inc?
The stock symbol for Atossa Therapeutics Inc is "ATOS."
What Stock Exchange Does Atossa Therapeutics Inc Trade On?
Atossa Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Atossa Therapeutics Inc a Good Stock to Buy?
Determining whether Atossa Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ATOS quote. (ISIN: US04962H7044)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.2262
2.4400
52 wk Range
1.7000
19.3500
ATOS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.22622.4400
52 wk Range
1.700019.3500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ATOS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
22.0000
Upside
+801.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 22.0000
(+801.64% Upside)
Atossa Therapeutics Inc Earnings Call Summary for Q4/2024
- Atossa Genetics Q4 2024 EPS of -0.04 beats -0.065 forecast; stock up 0.47% to $0.752
- Net loss reduced to $25.5M from $30.1M in 2023; operating expenses down to $27.6M from $31.4M
- Cash position strong at $71.1M; company prioritizing Zendoxifen development for breast cancer
- FDA consultations expected in 4-6 months; U.S. market focus with global expansion planned for 2026
- Analyst price targets range $4-$7; company maintains "Fair" financial health score of 2.45/5
Last Updated: 2025-03-25, 10:10 a/m
Read Full TranscriptEarnings
Latest Release
May 08, 2026
EPS / Forecast
-1.11 / -0.07
Revenue / Forecast
-- / --
Compare ATOS to Peers and Sector
Metrics to compare | ATOS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATOSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.6x | −2.6x | −0.4x | |
PEG Ratio | 0.01 | −0.04 | 0.00 | |
Price/Book | 0.7x | 2.6x | 2.6x | |
Price / LTM Sales | - | 11.4x | 3.0x | |
Upside (Analyst Target) | - | 161.5% | 53.2% | |
Fair Value Upside | Unlock | 1.2% | 9.5% | Unlock |
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Atossa Therapeutics (ATOS) Stock Price Today?
The Atossa Therapeutics stock price today is 2.4400 USD.
What Stock Exchange Does Atossa Therapeutics Trade On?
Atossa Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Atossa Therapeutics?
The stock symbol for Atossa Therapeutics is "ATOS."
What Is the Atossa Therapeutics Market Cap?
As of today, Atossa Therapeutics market cap is 20.5800M USD.
What Is Atossa Therapeutics's Earnings Per Share (TTM)?
The Atossa Therapeutics EPS (TTM) is -4.3711.
When Is the Next Atossa Therapeutics Earnings Date?
Atossa Therapeutics will release its next earnings report on Aug 17, 2026.
From a Technical Analysis Perspective, Is ATOS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Atossa Therapeutics Stock Split?
Atossa Therapeutics has split 3 times.
How Many Employees Does Atossa Therapeutics Have?
Atossa Therapeutics has 16 employees.
What is the current trading status of Atossa Therapeutics (ATOS)?
As of Jul 15, 2026, Atossa Therapeutics (ATOS) is trading at a price of 2.4400 USD, with a previous close of 2.2600 USD. The stock has fluctuated within a day range of 2.2262 USD to 2.4400 USD, while its 52-week range spans from 1.7000 USD to 19.3500 USD.
What Is Atossa Therapeutics (ATOS) Price Target According to Analysts?
The average 12-month price target for Atossa Therapeutics is 22.0000 USD, with a high estimate of 24 USD and a low estimate of 20 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +801.64% Upside potential.
What Is the ATOS After Hours Price?
ATOS's last after hours stock price is 2.4600 USD, the stock has decreased by 0.0200, or 0.8200%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.